Incyte (INCY) Cash & Equivalents Growth (1y) (2011 - 2026)
Powered by 
Analysis
Incyte (INCY) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 28.50% |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn | -57.58% |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn | 103.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 103.71% |
| Mar 31, 2026 | 78.25% |
| Dec 31, 2025 | 83.54% |
| Sep 30, 2025 | 88.25% |
| Jun 30, 2025 | 98.01% |
| Mar 31, 2025 | -41.97% |
| Dec 31, 2024 | -47.47% |
| Sep 30, 2024 | -59.59% |
| Jun 30, 2024 | -68.47% |
| Mar 31, 2024 | 18.62% |
| Dec 31, 2023 | 8.88% |
| Sep 30, 2023 | 19.94% |
| Jun 30, 2023 | 28.57% |
| Mar 31, 2023 | 25.00% |
| Dec 31, 2022 | 43.45% |
| Sep 30, 2022 | 34.60% |
| Jun 30, 2022 | 35.48% |
| Mar 31, 2022 | 35.14% |
| Dec 31, 2021 | 35.98% |
| Sep 30, 2021 | 33.47% |